Chinese Journal of Integrative Medicine, originally entitled 'Chinese Journal of Integrated Traditional and Western Medicine' (English Edition), was founded in 1995, and changed formally its name in 2003. This journal is supervised by State Administration of Traditional Chinese Medicine, sponsored by Chinese Association of Integrative Medicine and China Academy of Chinese Medical Sciences. It is the first international peer-reviewed monthly journal on integrative medicine included in Science Citation Index Expanded (SCI-E).
6 NÚMEROS AL AÑO + EXTRAORDINARIO CONGRESO
Para más información, consulte
Clinical Drug Investigation covers:Clinical trialsOutcomes researchPharmacoeconomics studiesPharmacoepidemiology studiesPharmacodynamic and pharmacokinetic studiesApplication of drug-delivery technology in healthcare
Clinical Neuropharmacology is the leading journal of reviews and original investigations in this field. The journal is devoted to the pharmacology of the nervous system in the broadest sense, with topics ranging from basic mechanisms of action, structure-activity relationships, drug metabolism, and pharmacokinetics, to such practical clinical problems as drug interactions, drug toxicity, and the therapeutics of specific syndromes or symptoms. Disorders often classified as psychiatric, as well as classical neurological disorders, are included. Website: www.clinicalneuropharm.com.
Clinical Pharmacokinetics is the major review journal in the area of clinical pharmacokinetics, the study of drug disposition in the human body, which is an integral part of drug development and rational use.
Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles and Reports in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.Commentaries and Point-Counterpoint provide a forum for perspectives in clinical pharmacology and therapeutics in the context of contemporary scientific, political, economic and social issues. State of the Art contributions summarize the latest advances in the science underpinning drug discovery, development, regulation and utilization. CPT highlights issues transforming the practice of clinical pharmacology, including ethics, education and public policy. Bench-to-bedside translation in therapeutics is presented in the context of clinical applications of basic pharmacology, discovery and translational medicine, and drug development.
Every paper has its own priorities. Be it rapid publication, strong circulation, society affiliation or the prestige of a high Impact Factor, we help pharmaceutical companies, medcomms agencies and medical writers identify the Informa Healthcare journal that will help them achieve their publication objectives.We actively encourage pre-submission discussions with our team and Informa Healthcare editors to ensure your submission process is as efficient and effective as possible. You are welcome to contact us directly to discuss your upcoming manuscripts. Alternately, if you would like to browse our portfolio of 168 journals, you can do so using the tool below.
Clinical Therapeutics is dedicated to the dissemination of reliable and evolving evidence derived from clinical pharmacology and other therapeutic approaches to an international audience of scientists and clinicians working in a variety of research, academic, and clinical practice settings. Providing such information is especially important in this era of harmonization and globalization of drug development. Clinical Therapeutics strives to achieve its mission by providing peer-reviewed, rapid publication of recent developments in drug therapies, as well as in-depth review articles on specific agents, treatment strategies, and disease states. Most articles are available online within 20 business days after acceptance. Articles appearing in Clinical Therapeutics are indexed by all major biomedical abstracting databases.Published articles range from pivotal studies exploring new chemical entities in large, multicenter trials to those exploring repurposing of marketed agents. Additionally, pilot studies; reports that assess drug safety and tolerability in all phases of development; new routes of administration and new formulations; pharmacokinetic, bioavailability, bioequivalence and biosimilarity; and changes in practice guidelines and standards, are all of interest for publication. Clinical Therapeutics also understands the importance of strengthening the body of evidence surrounding particular agents through the publication of replication studies, negative trials, and failed trials. Beyond the clinic, we seek reports that examine the real-world implications of therapeutics such as comparative effectiveness and pharmacoeconomics studies as well as work that has implications for health policy. Commentaries, which include perspectives and contemporary issues, are sought to offer a balance of viewpoints and scholarly opinion on a broad array of drug-related topics. Case reports, which remain a vital part of our mission, offer clinically valuable lessons. All manuscripts are peer reviewed by independent clinicians or scientists for clinical relevance, technical accuracy, methodological rigor, clarity, and objectivity using a blind review process.
Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.The following topics are covered in the journal:Unconventional design features of specific trials and their rationalePreliminary or full results of clinical trials with unconventional design featuresStatistical methods for all aspects of clinical trialsMethodologies for clinical trial operations including trial management and optimization; patient recruitment and retention; and trial quality monitoring and assessmentData management methodologies including data collection; database maintenance; data quality assurance; safety monitoring and risk management; and patient registriesRegulatory requirements and their impact on clinical trialsEthical and legal considerations in clinical trialsRisk-benefit, cost-effectiveness and decision analyses in clinical trialsContemporary Clinical Trials is unique in that it is outside the confines of disease specifications, and it strives to adapt and grow with an expanding clinical trials landscape as the needs of clinical research evolve in today's dynamic healthcare environment.Having taken upon the important role as a platform for knowledge exchange between experts in different disciplines related to clinical trials, the ultimate goal of Contemporary Clinical Trials is to advance this field of research for the benefit of patients.We look forward to receiving your contribution!Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com
The aim of this journal is to keep readers informed by providing cutting-edge reviews on key topics pertaining to cardiovascular risk. We use a systematic approach: international experts prepare timely articles on relevant topics that highlight the most important recent original publications.
We accomplish this aim by appointing Section Editors in major subject areas across the discipline of cardiovascular medicine to select topics for review articles by leading experts who emphasize recent developments and highlight important papers published in the past year. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.
Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal aims to publish the highest quality review articles, drug clinical trial studies and guest edited thematic issues in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy and drug clinical trial studies and guest edited thematic issues covering: new and existing drugs, therapies and medical devices.